First patient treated in fifth cohort of Anixa’s ovarian cancer trial

Phase 1Neutral

AI Analysis

Summary

Anixa Biosciences has treated the first patient in the fifth cohort of its Phase I clinical trial evaluating a CAR-T therapy for recurrent ovarian cancer.

Clinical Trial Data

Phase

Phase I

Outcome Details

First patient treated in fifth cohort

Importance:3/10

Sentiment:

0.00

CAR-T therapyovarian cancerPhase 1 trialpatient enrollment

Related Companies

$ANIX

Read the original article

Published by Clinical Trials Arena on July 7, 2026 10:01 AM

Read Original